Basel, September 17, 2024 – Novartis today announced that the US Food and Drug Administration (FDA) has approved Kisqali (ribociclib) in combination with an aromatase inhibitor (AI) for the adjuvant treatment of people with hormone…Original Article
FDA Approves Kisqali to Reduce Risk of Recurrence in People with HR+/HER2- Early Breast Cancer
